AMARIN CORP PLC\UK AMRN
This Annual Report on Form 10-K, or Annual Report, includes the registered and unregistered trademarks and service marks of other parties.
Amarin Corporation plc is a public limited company incorporated under the laws of England and Wales. Amarin Corporation plc was originally incorporated in England as a private limited company on March 1, 1989 under the Companies Act 1985, and re-registered in England as a public limited company on March 19, 1993.
Our principal office is located at One Central Plaza, 8th Floor, 36 Dame Street, Dublin 2, Ireland. Our registered office is located at One New Change, London EC4M 9AF, England. Our primary office in the United States is located at 440 Route 22, Bridgewater, NJ 08807, USA. Our telephone number at that location is (908) 719-1315.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $213.6M | $228.6M | $306.9M | $369.2M | $583.2M | $614.1M | $429.8M | $229.2M | $181.1M | $130.1M |
| Cost of revenue | — | — | — | — | $121.3M | $131.4M | $96.0M | $54.5M | $45.0M | $34.4M |
| Gross profit | $120.9M | $81.4M | $165.5M | $242.5M | $461.9M | $482.6M | $333.7M | $174.7M | $136.2M | $95.7M |
| R&D | $19.8M | $20.9M | $22.2M | $30.4M | $29.3M | $39.0M | $34.4M | $55.9M | $47.2M | $50.0M |
| SG&A | $115.0M | $152.3M | $199.9M | $304.4M | $408.3M | $463.3M | $323.6M | $227.0M | $134.5M | $111.4M |
| Total operating expenses | $171.0M | $173.2M | $233.1M | $348.4M | $451.4M | $502.3M | $358.0M | $282.9M | $181.7M | $161.3M |
| Operating income | -$50.2M | -$91.8M | -$67.6M | -$105.9M | $10.5M | -$19.7M | -$24.3M | -$108.2M | -$45.6M | -$65.6M |
| Interest expense | $7.0K | $7.0K | $8.0K | $15.0K | $129.0K | $2.6M | $6.6M | $8.9M | $9.8M | $18.7M |
| Pre-tax income | -$36.0M | -$77.2M | -$53.7M | -$103.8M | $11.3M | -$17.3M | -$22.5M | -$116.3M | -$54.8M | -$76.4M |
| Income tax | $2.8M | $5.0M | $5.4M | $2.0M | $3.6M | $745.0K | $164.0K | $96.0K | $13.0M | $10.0M |
| Net income | -$38.8M | -$87.0M | -$55.0M | -$105.8M | $7.7M | -$18.0M | -$22.6M | -$116.4M | -$67.9M | -$86.3M |
| EPS, basic | -0.09 | -0.20 | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 |
| EPS, diluted | -0.09 | -0.20 | -0.15 | -0.26 | 0.02 | -0.05 | -0.07 | -0.39 | -0.25 | -0.41 |
| Shares, diluted (wtd. avg.) | $415.0M | $410.9M | $407.7M | $401.2M | $402.5M | $381.8M | $342.5M | $297.2M | $270.7M | $211.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $134.7M | $121.0M | $199.3M | $217.7M | $219.5M | $187.0M | $644.6M | $249.2M | $73.6M | $98.3M |
| Short-term investments | $167.9M | $173.2M | $121.4M | $91.7M | $234.7M | $314.0M | — | — | — | — |
| Receivables | $126.8M | $122.3M | $133.6M | $131.0M | $163.7M | $154.6M | $116.4M | $66.5M | $45.3M | $20.0M |
| Inventory | $195.9M | $166.0M | $258.6M | $228.7M | $234.7M | $188.9M | $76.8M | $57.8M | $30.3M | $20.5M |
| Total current assets | $649.9M | $595.4M | $725.0M | $689.1M | $878.7M | $879.2M | $855.0M | $378.0M | $153.3M | $146.3M |
| Property, plant and equipment | $12.0K | $16.0K | $114.0K | $874.0K | $1.4M | $2.0M | $2.4M | $63.0K | $28.0K | $78.0K |
| Other intangibles | $13.4M | $16.4M | $19.3M | $21.8M | $23.5M | $13.8M | $15.3M | $7.5M | $8.1M | $8.8M |
| Total assets | $670.8M | $685.3M | $831.7M | $886.2M | $1.07B | $966.0M | $882.2M | $385.7M | $161.6M | $167.0M |
| Accounts payable | $45.4M | $40.4M | $52.8M | $64.6M | $114.9M | $105.9M | $50.0M | $37.6M | $25.2M | $6.1M |
| Short-term debt | — | — | — | — | $0 | $0 | $50.1M | $34.2M | $22.3M | $15.9M |
| Total current liabilities | $194.5M | $179.9M | $259.3M | $259.5M | $370.7M | $307.4M | $242.2M | $157.3M | $108.5M | $76.2M |
| Long-term debt | — | — | — | — | — | — | $49.7M | $46.1M | $70.8M | $85.2M |
| Total liabilities | $211.5M | $199.2M | $279.6M | $290.8M | $401.0M | $338.5M | $273.9M | $233.4M | $226.7M | $176.1M |
| Retained earnings | -$1.71B | -$1.67B | -$1.59B | -$1.53B | -$1.42B | -$1.43B | -$1.41B | -$1.39B | -$1.27B | -$1.20B |
| Total equity | $459.3M | $486.2M | $552.1M | $595.3M | $667.1M | $627.5M | $608.3M | $152.3M | -$65.1M | -$9.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.7M | -$31.0M | $6.9M | -$180.1M | -$66.5M | -$21.7M | -$9.4M | -$94.7M | -$32.8M | -$71.8M |
| Depreciation and amortisation | — | $100.0K | $200.0K | $600.0K | $600.0K | $600.0K | $200.0K | — | $100.0K | $100.0K |
| Stock-based compensation | $13.9M | $17.7M | $15.6M | $26.2M | $36.9M | $45.8M | $30.9M | $18.8M | $14.0M | $13.6M |
| Capital expenditure | — | — | — | — | — | $252.0K | $2.5M | $58.0K | $12.0K | $21.0K |
| Investing cash flow | $8.8M | -$46.0M | -$25.5M | $175.3M | $104.1M | -$377.0M | -$2.5M | -$58.0K | -$12.0K | -$21.0K |
| Financing cash flow | -$2.0M | -$1.4M | $230.0K | -$379.0K | -$5.1M | -$58.9M | $409.6M | $271.3M | $8.2M | $63.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-151417.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |